⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
GANX News
Gain Therapeutics, Inc. Common Stock
Form 8-K
sec.gov
GANX
Gain Therapeutics Reports Financial Results for Second Quarter 2026 and Provides Corporate Update
globenewswire.com
GANX
Form 8-K
sec.gov
GANX
Gain Therapeutics CEO Gene Mack Issues Letter to Shareholders and Provides Operational Update
globenewswire.com
GANX
Form 8-K
sec.gov
GANX
Gain Therapeutics Receives FDA Clearance of IND to Advance GT-02287 into Phase 2 Clinical Development for Parkinson’s Disease
globenewswire.com
GANX
Form 8-K
sec.gov
GANX
Gain Therapeutics to Present at H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit
globenewswire.com
GANX
Form 8-K
sec.gov
GANX
Gain Therapeutics Presents Positive Interim Data from Phase 1b Clinical Study of GT-02287 at 3rd International GBA1 Meeting 2026
globenewswire.com
GANX